A
Andrea L. Cathcart
Publications - 18
Citations - 1004
Andrea L. Cathcart is an academic researcher. The author has contributed to research in topics: Tenofovir alafenamide & Medicine. The author has an hindex of 8, co-authored 10 publications receiving 567 citations.
Papers
More filters
Journal ArticleDOI
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
Maria Buti,Edward Gane,Wai-Kay Seto,Henry Lik-Yuen Chan,Wan-Long Chuang,Tatjana Stepanova,Aric J. Hui,Young-Suk Lim,R. Mehta,Harry L. A. Janssen,Subrat K. Acharya,John F. Flaherty,Benedetta Massetto,Andrea L. Cathcart,Kyungpil Kim,Anuj Gaggar,G. Mani Subramanian,John G. McHutchison,Calvin Q. Pan,Maurizia Rossana Brunetto,Namiki Izumi,Patrick Marcellin +21 more
TL;DR: The primary efficacy endpoint was the proportion of patients who had HBV DNA less than 29 IU/mL at week 48 in those who received at least one dose of study drug; the study was powered to show non-inferiority with a 10% efficacy margin of tenofovir alafenamide compared with ten ofovir disoproxil fumarate.
Journal ArticleDOI
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
Kosh Agarwal,Maurizia Rossana Brunetto,Wai-Kay Seto,Young-Suk Lim,Scott Fung,Patrick Marcellin,Sang Hoon Ahn,Namiki Izumi,Wan-Long Chuang,Ho Bae,Manoj Sharma,Harry L.A. Janssen,Harry L.A. Janssen,Calvin Q. Pan,Mustafa Kemal Çelen,Norihiro Furusyo,Shalimar,Ki Tae Yoon,Huy N. Trinh,John F. Flaherty,Anuj Gaggar,Audrey H. Lau,Andrea L. Cathcart,Lanjia Lin,Neeru Bhardwaj,Vithika Suri,G. Mani Subramanian,Edward Gane,Maria Buti,Henry Lik-Yuen Chan +29 more
TL;DR: In patients with HBV infection, TAF remained as effective as TDF, with continued improved renal and bone safety, two years after the initiation of treatment.
Journal ArticleDOI
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Anil Gupta,Yaneicy Gonzalez-Rojas,Erick Saúl Ríos Juárez,Manuel Crespo Casal,Jaynier Moya,Diego Rodrigues Falci,Elias H. Sarkis,Joel Solis,Nicola Scott,Andrea L. Cathcart,S. Parra,Jennifer E Sager,Daren Austin,Amanda Peppercorn,Elizabeth Alexander,Wendy W. Yeh,Cynthia Brinson,Melissa Aldinger,Adrienne E Shapiro +18 more
TL;DR: Among nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression, a single intravenous dose of sotrovimab, compared with placebo, significantly reduced the risk of a composite end point of all-cause hospitalization or death through day 29.
Journal ArticleDOI
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
Patrick Marcellin,David Wong,William Sievert,Peter Buggisch,Jörg Petersen,Robert Flisiak,Michael Manns,Kelly Kaita,Zahari Krastev,Samuel S. Lee,Andrea L. Cathcart,Gerald Crans,Marjoleine L. Op den Brouw,Belinda Jump,Anuj Gaggar,John F. Flaherty,Maria Buti +16 more
TL;DR: The efficacy and safety profiles of TDF treatment for up to 10 years in a well‐described cohort of CHB patients are described.
Journal ArticleDOI
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.
Andrea L. Cathcart,Henry Lik-Yuen Chan,Neeru Bhardwaj,Yang Liu,Patrick Marcellin,Calvin Q. Pan,Shalimar,Maria Buti,Stephanie Cox,Bandita Parhy,Eric Zhou,Ross Martin,Silvia Chang,Lanjia Lin,John F. Flaherty,Kathryn M. Kitrinos,Anuj Gaggar,Namiki Izumi,Young-Suk Lim +18 more
TL;DR: After 96 weeks, the proportion of patients achieving virus suppression (HBV DNA < 69 IU/ml) was similar across treatment groups, and no substitutions associated with resistance to TAF or TDF were detected.